The Optimal Duration of Adjuvant Endocrine Therapy for Early Stage Breast Cancer—With What Drugs and for How Long?
- 4 January 2014
- journal article
- research article
- Published by Springer Nature in Current Oncology Reports
- Vol. 16 (1) , 1-8
Abstract
Adjuvant endocrine therapy has made a significant impact in improving overall survival for women with hormone receptor (HR)-positive breast cancer. The anti-estrogen tamoxifen is the most widely used therapy, although in post-menopausal women, aromatase inhibitors (AIs) have further improved outcomes either as an alternative to tamoxifen for 5 years, or given in sequential fashion following initial tamoxifen therapy. However, late recurrence remains perhaps the biggest risk in HR-positive breast cancer, with more than half all recurrences occurring beyond 5 years since primary diagnosis. As such, the current debate is whether extended AI or prolonged tamoxifen therapy should be given, and if so, to whom. We review some of the recent studies that have addressed this question and demonstrated further reduction in risk of recurrence, and discuss the clinical issues that face women and their health care providers in determining who should use which drug, and for how long.Keywords
This publication has 42 references indexed in Scilit:
- Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trialThe Lancet, 2013
- Longer-Term Outcomes of Letrozole Versus Placebo After 5 Years of Tamoxifen in the NCIC CTG MA.17 Trial: Analyses Adjusting for Treatment CrossoverJournal of Clinical Oncology, 2012
- Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-upThe Lancet Oncology, 2011
- The St. Gallen Prize Lecture 2011: Evolution of long-term adjuvant anti-hormone therapy: consequences and opportunitiesThe Breast, 2011
- Letrozole Therapy Alone or in Sequence with Tamoxifen in Women with Breast CancerNew England Journal of Medicine, 2009
- Hazard of recurrence and adjuvant treatment effects over time in lymph node-negative breast cancerBreast Cancer Research and Treatment, 2008
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsThe Lancet, 2005
- A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast CancerNew England Journal of Medicine, 2004
- A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast CancerNew England Journal of Medicine, 2003
- A New Anti-oestrogenic Agent in Late Breast Cancer: An Early Clinical Appraisal of ICI46474British Journal of Cancer, 1971